Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Summary
This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.
Official title: An Open-label, Multi-center Phase Ib/III Study Evaluating the Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2022-09-20
Completion Date
2027-07-31
Last Updated
2025-01-27
Healthy Volunteers
No
Conditions
Interventions
IBI351
recommended dose, po
Cetuximab
500mg/m\^2, Q2W, day1, i.v.
pemetrexed
500mg/m\^2, Q3W, day1, i.v.
Carboplatin
AUC=5, Q3W, day1, i.v.
Sintilimab
200mg, Q3W, day1, i.v.
cis-platinum
75mg/m\^2, Q3W, day1, i.v.
Locations (1)
Jilin Province Cancer Hospital
Jilin, Changchun, China